<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22193283</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>252</EndPage><MedlinePgn>245-252</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2011.12.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(11)00522-5</ELocationID><Abstract><AbstractText>Dengue virus (DENV), a mosquito-borne member of the family Flaviviridae, is a significant global pathogen affecting primarily tropical and subtropical regions of the world and placing tremendous burden on the limited medical infrastructure that exists in many of the developing countries located within these regions. Recent outbreaks in developed countries, including Australia (Hanna et al., 2009), France (La Ruche et al., 2010), Taiwan (Kuan et al., 2010), and the USA (CDC, 2010), lead many researchers to believe that continued emergence into more temperate latitudes is likely. A primary concern is that there are no approved vaccines or antiviral therapies to treat DENV infections. Since the viral NS2B-NS3 protease (DENV NS2B-NS3pro) is required for virus replication, it provides a strategic target for the development of antiviral drugs. In this study, proof-of-concept high-throughput screenings (HTSs) were performed to unambiguously identify dengue 2 virus (DEN2V) NS2B-NS3pro inhibitors from a library of 2000 compounds. Validation screens were performed in parallel to concurrently eliminate insoluble, auto-fluorescing, and/or nonspecific inhibitors. Kinetic analyses of the hits revealed that parallel substrate fluorophore (AMC) interference controls and trypsin inhibition controls were able to reduce false positive rates due to solubility and fluorophore interference while the trypsin inhibition control additionally eliminated non-specific inhibitors. We identified five DEN2V NS2B-NS3pro inhibitors that also inhibited the related West Nile virus (WNV) protease (NS2B-NS3pro), but did not inhibit the trypsin protease. Biochemical analyses revealed various mechanisms of inhibition including competitive and mixed noncompetitive inhibition, with the lowest K(i) values being 12&#xb1;1.5 &#x3bc;M for DEN2V NS2B-NS3pro and 2&#xb1;0.2 &#x3bc;M for WNV NS2B-NS3pro.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Suzanne M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watowich</LastName><ForeName>Stanley J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, United States. Electronic address: watowich@xray.utmb.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI066160</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI066160-02S1</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI065396</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 T32 AI065396-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI066160-02</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007093</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI066160</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C080102">NS2B protein, flavivirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C504449">NS3 protease, dengue virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22193283</ArticleId><ArticleId IdType="mid">NIHMS344894</ArticleId><ArticleId IdType="pmc">PMC3266433</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2011.12.003</ArticleId><ArticleId IdType="pii">S0166-3542(11)00522-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alleman M, Twim-Danso N, Thylefors B. The Mectizan donation program -highlights from 2005. Filaria J. 2006;5:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, Castro O, Kouri G, Halstead SB, Guzman MG. Dengue hemorrhagic fever caused by sequential dengue 1&#x2013;3 virus infections over a long time interval: Havana epidemic, 2001&#x2013;2002. Am J Trop Med Hyg. 2006;75:1113&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">17172378</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahour A, Falgout B, Lai CJ. Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions are mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease. J Virol. 1992;66:1535&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240879</ArticleId><ArticleId IdType="pubmed">1531368</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . Locally acquired Dengue--Key West, Florida, 2009&#x2013;2010. MMWR Morb Mortal Wkly Rep. 2010;59:577&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">20489680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Nestorowicz A, Amberg SM, Rice CM. Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol. 1993;67:6797&#x2013;6807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC238121</ArticleId><ArticleId IdType="pubmed">8411382</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthana-sombat C, Katzenmeier G. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun. 2005;330:1237&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823576</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P, Schiering N, D&#x2019;Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol. 2006;13:372&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol. 1991;65:2467&#x2013;2475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240601</ArticleId><ArticleId IdType="pubmed">2016768</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields B, Knipe D, Howley P, Chanock R, Melnick J, Monath T, Roizman B, Strauss S. Field&#x2019;s Virology. 3. Lippincott Williams &amp; Wilkins; Philadelphia: 1996.</Citation></Reference><Reference><Citation>Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna JN, Ritchie SA, Richards AR, Humphreys JL, Montgomery BL, Ehlers GJ, Pyke AT, Taylor CT. Dengue in north Queensland, 2005&#x2013;2008. Commun Dis Intell. 2009;33:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">19877538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3:e381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637543</ArticleId><ArticleId IdType="pubmed">19221595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan MM, Lin T, Chuang JH, Wu HS. Epidemiological trends and the effect of airport fever screening on prevention of domestic dengue fever outbreaks in Taiwan, 1998&#x2013;2007. Int J Infect Dis. 2010;14:e693&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110484</ArticleId><ArticleId IdType="pubmed">20656647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal Biochem. 1996;237:260&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660575</ArticleId></ArticleIdList></Reference><Reference><Citation>La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, Despres P, Lenglet A, Jourdain F, Leparc-Goffart I, Charlet F, Ollier L, Mantey K, Mollet T, Fournier JP, Torrents R, Leitmeyer K, Hilairet P, Zeller H, Van Bortel W, Dejour-Salamanca D, Grandadam M, Gastellu-Etchegorry M. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill. 2010;15:19676.</Citation><ArticleIdList><ArticleId IdType="pubmed">20929659</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR, Fairlie DP. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem. 2001;276:45762&#x2013;45771.</Citation><ArticleIdList><ArticleId IdType="pubmed">11581268</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP, Harris JL, Vasudevan SG. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem. 2005;280:28766&#x2013;28774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15932883</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12:147&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88911</ArticleId><ArticleId IdType="pubmed">9880479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci. 2009;66:3821&#x2013;3826.</Citation><ArticleIdList><ArticleId IdType="pubmed">19701717</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinari G, Soloneski S, Reigosa MA, Larramendy ML. In vitro genotoxic and cytotoxic effects of ivermectin and its formulation on Chinese hamster ovary (CHOK1) cells. J Hazard Mater. 2009;165:1074&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller NH, Yon C, Ganesh VK, Padmanabhan R. Characterization of the West Nile virus protease substrate specificity and inhibitors. Int J Biochem Cell Biol. 2007;39:606&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogoussan KT, Hopkins A. Mectizan procurement and delivery for onchocerciasis mass drug administration programmes. Acta Trop. 2010;120(Suppl 1):S173&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20974105</ArticleId></ArticleIdList></Reference><Reference><Citation>Otoguro K, Liu ZX, Fukuda K, Li Y, Iwai Y, Tanaka H, Omura S. Screening for new nematocidal substances of microbial origin by a new method using the pine wood nematode. J Antibiot (Tokyo) 1988;41:573&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">3372364</ArticleId></ArticleIdList></Reference><Reference><Citation>Pipano E. Recent developments in the control of ectoparasites and endoparasites of dogs and cats. Israel Journal of Veterinary Medicine. 2002;58:2&#x2013;3.</Citation></Reference><Reference><Citation>Tomlinson SM, Malmstrom RD, Watowich SJ. New approaches to structure-based discovery of dengue protease inhibitors. Infect Disord Drug Targets. 2009a;9:327&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">19519486</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res. 2009b;82:110&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680748</ArticleId><ArticleId IdType="pubmed">19428601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Watowich SJ. Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease. Biochemistry. 2008;47:11763&#x2013;11770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648976</ArticleId><ArticleId IdType="pubmed">18855422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Watowich SJ. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Antiviral Res. 2011;89:127&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026091</ArticleId><ArticleId IdType="pubmed">21185332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011;16:192&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">21297106</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. 2010  http://www.who.int/mediacentre/factsheets/fs117/en/</Citation></Reference><Reference><Citation>Xie J, Nair A, Hermiston TW. A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types. Toxicol In Vitro. 2008;22:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928190</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother. 2011;55:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019636</ArticleId><ArticleId IdType="pubmed">20937790</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates DM, Wolstenholme AJ. An ivermectin-sensitive glutamate-gated chloride channel subunit from Dirofilaria immitis. Int J Parasitol. 2004;34:1075&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313134</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox JE, Ma NL, Ehrhardt C, Lim SP, Vasudevan SG, Keller TH. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bio-org Med Chem Lett. 2006;16:40&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther. 2006;5:2234&#x2013;2240.</Citation><ArticleIdList><ArticleId IdType="pubmed">16985057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem. 2000;275:9963&#x2013;9969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>